P074 | Innovative mrd detection and immune profiling in relapsed cll treated with rituximab-venetoclax: insights from the “dedalus” protocol
Background. Fixed-duration Rituximab (R) and Venetoclax (Ven) therapy has improved outcomes in chronic lymphocytic leukemia (CLL), achieving a 7-year overall survival of 69.6% and effective MRD eradication. Accurate minimal residual disease (MRD) assessment is essential to monitor treatment response...
Gardado en:
| Autor Principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Ferrata Storti Foundation
2026-03-01
|
| Series: | Haematologica |
| Acceso en liña: | https://haematologica.org/article/view/13333 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|